The term " Disreputable Pharma" has surfaced recently, sparking a heated debate surrounding some pharmaceutical entities. Allegations of deceptive marketing practices, inflated drug pricing , and a apparent disregard for patient safety have led to increasing scrutiny from regulators , patient adv